France – Radiotherapy devices and supplies – FOURNITURE D’EQUIPEMENTS ET LOGICIELS DE RADIOTHERAPIE ET PRESTATIONS ASSOCIEES

France – Laboratory reagents – 051_2026_AO_Lecteurs glycémie_cétonémie

France – Functional support – SALLE HYPOXIQUE DE REEDUCATION

France – Domestic animal nurseries – CONTROLE_PEUPLEMENT_ANIMALIER

France – Imaging equipment for medical, dental and veterinary use – Fourniture, livraison et mise en service de scanners intraoraux sans fil pour les membres des Hôpitaux du Hainaut-Cambrésis

France – Dental consumables – Fourniture de matériels et consommables pour l’enseignement et les travaux pratiques de l’Ecole de Médecine Dentaire de Marseille

France – Toilet paper, handkerchiefs, hand towels and serviettes – Fourniture de produits d'entretien pour les services du CD64, du SDIS64, de la MDPH64 et 27 Collèges publics du Département des Pyrénées-Atlantiques

Expected Outcome: This action will establish a strategic European initiative to develop scalable, modular, and interoperable photonic quantum computing platforms. Proposals for this topic are expected to address and provide credible solutions to at least two major technical roadblocks currently limiting the advancement of photonic quantum computing such as: The lack of deterministic, high-efficiency photonic entanglement and loss-tolerant architectures suitable for fault-tolerant scaling The absence of a standardised, integrated control stack combining photonic hardware, firmware, and system software with reliable benchmarking across platforms Project results are expected to contribute to the following expected outcomes: By 2028, demonstration of a photonic NISQ processor with ≥100 photonic qubits, integrating deterministic single-photon sources, low-loss waveguides, on-chip detectors, and a firmware stack (scheduler, controller, compiler), validated via hardware-agnostic benchmarks and hybrid photonic-HPC applications demonstrating classical-quantum crossover By 2030, delivery of a full-stack, high-connectivity photonic quantum computer, with modular scalability, integrated…

Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new…

Expected Outcome: Successful proposals will contribute to the Chemicals Strategy for Sustainability and Ecodesign for Sustainable Products Regulation, the Chemical Industry Action Plan, the Clean Industrial Deal as well as the Horizon Europe Mission "Restore our Ocean and Waters by 2030" in particular to Objective 2: "Prevent and eliminate pollution of our oceans, Seas and waters". Projects results are expected to contribute to the following expected outcomes: Full industrial scale biorefinery and related value chain(s) to produce SSbD bio-based solutions for home and/or personal care sector with significantly improved sustainability. Wider availability of bio-based products in home and/or personal care sector meeting both regulatory standards and technical performance requirements. Increased consumer/end user acceptance of bio-based solutions, facilitating market uptake. Contribution to the EU strategic autonomy, resilience and competitiveness, reducing the fossil feedstock dependence for chemicals production and minimising biomass imports dependencies. Scope: The home and personal care sector, including fast-moving consumer goods (FMCG) and cosmetics, is a key industry where…

Expected Impact: The action under this topic is expected to achieve the following impacts and contribute to the following EU policies/initiatives: deliver innovative, early technology solutions that contribute to addressing strategic unmet public health needs across multiple therapy areas to improve prevention, early diagnosis, and treatment; leverage the unique network and scale of IHI JU members to create a pipeline to support innovative startups in the health industry, fully integrated into European initiatives in support of start-ups and entrepreneurship; drive early cross-sector health R&D and innovation to strengthen the European healthcare industry’s global competitiveness, contributing to the EU Industrial Strategy and Pharmaceutical Strategy objectives; create a sustainable network of European healthcare incubators to guide and support highly talented and innovative early-stage companies; harness digital health and data-sharing technologies (e.g., AI and big data) to enable interoperable health solutions, contributing to the European Health Data Space (EHDS) and improved evidence based care;- the action should generate a portfolio of early‑stage companies that have…